View in EDS PDF Full Text

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

Saved in:
Bibliographic Details
Title: Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
Authors: Richter, Joshua1 (AUTHOR) joshua.richter@mountsinai.org, Lee, Hans C.2 (AUTHOR), Jagannath, Sundar1 (AUTHOR), Zonder, Jeffrey A.3 (AUTHOR), Hoffman, James E.4 (AUTHOR), Zhou, Zheng-Yi5 (AUTHOR), Garcia-Horton, Viviana5 (AUTHOR), Fillbrunn, Mirko5 (AUTHOR), Wang, Hongjue5 (AUTHOR), Mattera, Matthew5 (AUTHOR), Inocencio, Timothy J.6 (AUTHOR), Xu, Yingxin6 (AUTHOR), Harnett, James6 (AUTHOR), Roccia, Tito6 (AUTHOR), Kroog, Glenn S.6 (AUTHOR), Rodriguez Lorenc, Karen6 (AUTHOR), Knorr, Kate6 (AUTHOR), Ma, Qiufei6 (AUTHOR), Bumma, Naresh7 (AUTHOR)
Source: Leukemia & Lymphoma. Jul2026, p1-13. 13p. 3 Illustrations.
Database: Academic Search Ultimate
Description
ISSN:10428194
DOI:10.1080/10428194.2026.2688561